c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia - PubMed (original) (raw)
c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia
M Gari et al. Br J Haematol. 1999 Jun.
Free article
Abstract
Genomic DNA from 60 cases of acute myeloid leukaemia (AML) was screened for mutations in the c-kit gene. DNA from all 21 exons was subjected to polymerase chain reaction (PCR) amplification and analysis by conformation sensitive gel electrophoresis (CSGE); exons showing altered CSGE patterns were then sequenced. Mutations were identified only in those patients with inv(16) (3/7 cases) or t(8;21) (1/2 cases) and comprised three in-frame deletion plus insertion mutations (exon 8) and one point mutation (exon 10, GTA --> ATA, Val530Ile). Exons 8 and 10 were then analysed in 31 further cases of inv(16) (n = 14) and t(8;21) (n = 17), revealing four additional exon 8 in-frame deletion plus insertion mutations, all of which were in cases of inv(16). All exon 8 in-frame deletion plus insertion mutations (n = 7) involved the loss or replacement of the codon for Asp419 which is highly conserved cross species and is located in the receptor's extracellular domain. The high frequency of the c-kit proto-oncogene exon 8 deletion plus insertion mutations in AML suggests an essential role for this region of the receptor's extracellular domain. The association with inv(16) invites speculation as to the link between these two changes in the pathogenesis of AML.
Similar articles
- KIT proto-oncogene exon 8 deletions at codon 419 are highly frequent in acute myeloid leukaemia with inv(16) in Indian population.
Hussain SR, Naqvi H, Mahdi F, Bansal C, Babu SG. Hussain SR, et al. Mol Biotechnol. 2013 Jun;54(2):461-8. doi: 10.1007/s12033-012-9584-x. Mol Biotechnol. 2013. PMID: 22825855 - Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.
Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, Gari MA, Peake IR, Löwenberg B, Reilly JT. Care RS, et al. Br J Haematol. 2003 Jun;121(5):775-7. doi: 10.1046/j.1365-2141.2003.04362.x. Br J Haematol. 2003. PMID: 12780793 - Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A. Riera L, et al. Oncol Rep. 2013 May;29(5):1867-72. doi: 10.3892/or.2013.2328. Epub 2013 Mar 5. Oncol Rep. 2013. PMID: 23467883 - Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, Shams SF, Shakeri S. Ayatollahi H, et al. Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):1-7. doi: 10.1016/j.hemonc.2016.08.005. Epub 2016 Sep 3. Hematol Oncol Stem Cell Ther. 2017. PMID: 27613372 Review. - Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?
Reilly JT. Reilly JT. Br J Haematol. 2005 Jan;128(1):18-34. doi: 10.1111/j.1365-2141.2004.05236.x. Br J Haematol. 2005. PMID: 15606546 Review.
Cited by
- Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.
Shukla M, Abdul-Hay M, Choi JH. Shukla M, et al. Biomedicines. 2024 Aug 6;12(8):1768. doi: 10.3390/biomedicines12081768. Biomedicines. 2024. PMID: 39200232 Free PMC article. Review. - Identification and in silico analysis of noval alteration Arg420Gly in KIT proto oncogene among acute myeloid leukemia patients.
Akram AM, Hassan M, Chaudhary A, Hayat S, Ali Q, Hussain T, Zafar A, Javed MA. Akram AM, et al. Sci Rep. 2022 Nov 10;12(1):19252. doi: 10.1038/s41598-022-23934-y. Sci Rep. 2022. PMID: 36357474 Free PMC article. - Design and application of a knowledge network for automatic prioritization of drug mechanisms.
Mayers M, Tu R, Steinecke D, Li TS, Queralt-Rosinach N, Su AI. Mayers M, et al. Bioinformatics. 2022 May 13;38(10):2880-2891. doi: 10.1093/bioinformatics/btac205. Bioinformatics. 2022. PMID: 35561182 Free PMC article. - Role of Biomarkers in FLT3 AML.
Nitika, Wei J, Hui AM. Nitika, et al. Cancers (Basel). 2022 Feb 24;14(5):1164. doi: 10.3390/cancers14051164. Cancers (Basel). 2022. PMID: 35267471 Free PMC article. Review. - Comprehensively analyze the expression and prognostic role for ten-eleven translocations (TETs) in acute myeloid leukemia.
Huang Y, Wei J, Huang X, Zhou W, Xu Y, Deng DH, Cheng P. Huang Y, et al. Transl Cancer Res. 2020 Nov;9(11):7259-7283. doi: 10.21037/tcr-20-3149. Transl Cancer Res. 2020. PMID: 35117329 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials